Safety, Efficacy, and Pharmacokinetics of Agalsidase Alfa in Treatment-Naive Chinese Patients with Fabry Disease: 52-Week Phase 3, Open-Label, Single-Arm Study.
Data from this 52-week study support the use of agalsidase alfa as a long-term treatment option for Chinese patients with Fabry disease and safety, efficacy, and pharmacokinetic profiles were consistent with studies in other populations.